Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM

Condition:   Type 2 Diabetes Interventions:   Drug: IBI362;   Drug: Placebo;   Drug: Dulaglutide Sponsor:   Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials